<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03570658</url>
  </required_header>
  <id_info>
    <org_study_id>YP39406</org_study_id>
    <nct_id>NCT03570658</nct_id>
  </id_info>
  <brief_title>A Double-Blind Single-Ascending Dose (SAD) and Multiple-Ascending Dose (MAD) Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7049389 in Healthy Chinese Participants</brief_title>
  <official_title>A Randomized, Sponsor-Open, Investigator-Blinded, Subject-Blinded, Placebo-Controlled, Single-Ascending Dose (SAD) and Multiple-Ascending Dose (MAD) Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7049389 in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and tolerability of RO7049389 compared to placebo in
      single- and multiple-ascending doses in healthy Chinese participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 24, 2018</start_date>
  <completion_date type="Actual">January 28, 2019</completion_date>
  <primary_completion_date type="Actual">January 28, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>From the date of first administered dose through 28 days after the last administered dose.</time_frame>
    <description>An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of RO7049389</measure>
    <time_frame>At pre-defined intervals on Day 1 (SAD) and Day 14 (MAD)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Observed Plasma Concentration (Tmax) of RO7049389</measure>
    <time_frame>At pre-defined intervals on Day 1 (SAD) and Day 14 (MAD)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration vs Time Curve to Last Measurable Concentration (AUClast) of RO7049389</measure>
    <time_frame>At pre-defined intervals on Day 1 (SAD) and Day 14 (MAD)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration vs Time Curve Extrapolated to Infinity (AUC0-inf)</measure>
    <time_frame>At pre-defined intervals on Day 1 (SAD) and Day 14 (MAD)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Half-Life (T1/2) of RO7049389</measure>
    <time_frame>At pre-defined intervals on Day 1 (SAD) and Day 14 (MAD)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL/F) of RO7049389</measure>
    <time_frame>At pre-defined intervals on Day 1 (SAD)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Plasma Concentration (Ctrough) of RO7049389</measure>
    <time_frame>At pre-defined intervals on Day 14 (MAD)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Index of RO7049389</measure>
    <time_frame>At pre-defined intervals on Day 14 (MAD)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration vs Time Curve for a Dosing Interval (AUCtau)</measure>
    <time_frame>At pre-defined intervals on Day 14 (MAD)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Hepatitis B Virus</condition>
  <arm_group>
    <arm_group_label>Single-Ascending Dose (SAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of RO7049389.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple-Ascending Dose (MAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive multiple doses of RO7049389.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive either a single dose (SAD cohorts) or multiple doses (MAD cohorts) of placebo matched to RO7049389.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7049389</intervention_name>
    <description>RO7049389 will be administered orally either as a single dose (SAD) or as multiple doses defined by the SAD portion of the study (MAD).</description>
    <arm_group_label>Multiple-Ascending Dose (MAD)</arm_group_label>
    <arm_group_label>Single-Ascending Dose (SAD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered orally at a dose and frequency matched to RO7049389.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Chinese healthy male and female subjects, 18 to 60 years of age, inclusive.

          -  A Body Mass Index (BMI) of between 19 to 27 kg/m2 inclusive, and a body weight of at
             least 45 kg.

          -  Women should be of non-childbearing potential. Female subjects must be either
             surgically sterile (by means of hysterectomy and/or bilateral oophorectomy) or
             post-menopausal for at least one year (defined as amenorrhea &gt;/=12 consecutive months
             without another cause, and confirmed by follicle stimulating hormone level &gt;35
             mIU/mL).

          -  For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use
             contraceptive measures, and agreement to refrain from donating sperm

        Exclusion Criteria

          -  Pregnant (positive pregnancy test) or lactating women, and male subjects with partners
             who are pregnant or lactating.

          -  History or symptoms of any clinically significant gastrointestinal, renal, hepatic,
             broncho-pulmonary, neurological, psychiatric, cardio-vascular, endocrinological,
             hematological or allergic disease, metabolic disorder, cancer or cirrhosis.

          -  Personal history of congenital long QT syndrome or family history of sudden death.

          -  History of Gilbert's syndrome.

          -  History of having received or currently receiving any systemic anti-neoplastic
             (including radiation) or immune-modulatory treatment (including systemic oral or
             inhaled corticosteroids) &lt;/=6 months prior to the first dose of study drug or the
             expectation that such treatment will be needed at any time during the study.

          -  Subjects who have had significant acute infection, e.g., influenza, local infection,
             acute gastrointestinal symptoms or any other clinically significant illness within two
             weeks of dose administration.

          -  Any confirmed significant allergic reactions (urticaria or anaphylaxis) against any
             drug, or multiple drug allergies (non-active hay fever is acceptable).

          -  Electrocardiogram (ECG) with QRS and/or T-wave judged to be unfavorable for a
             consistently accurate QT measurement (e.g., neuromuscular artifact that cannot be
             readily eliminated, arrhythmias, indistinct QTS onset, low amplitude T-wave, merged T-
             and U waves, prominent U-waves)

          -  Creatinine clearance (CrCl) &lt;/=70 mL/min (using the Cockcroft-Gault formula)

          -  Positive test at screening of any of the following: hepatitis A (HAV IgM Ab),
             hepatitis B (HBsAg), hepatitis C (HCV RNA or HCV Ab) or human immunodeficiency virus 1
             and 2 (HIV Ab).

          -  Participation in an investigational drug or device study within 90 days prior to
             screening or more than 4 times per year.

          -  Donation or loss of blood over 500 mL within 3 months prior to screening.

          -  Any suspicion or history of drug and/or alcohol abuse within the last year.

          -  History (within 3 months of screening) of alcohol consumption exceeding two standard
             drinks per day on average (1 standard drink = 10 grams of alcohol). Alcohol
             consumption will be prohibited at least 48 hours before screening, 48 hours before and
             48 hours after each dose, and 48 hours before each scheduled visit.

          -  Use of &gt;5 cigarettes or equivalent nicotine-containing product per day.

          -  Taking any prescribed or over-the-counter medications (including vitamins or herbal
             remedies) within 2 weeks of first dosing or within 5 times the elimination half-life
             of the medication prior to first dosing (whichever is longer). Occasional
             acetaminophen/paracetamol is allowed.

          -  Subjects under judicial supervision, guardianship or curatorship.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Huashan Hospital Affiliated to Fudan University</name>
      <address>
        <city>Shanghai City</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 18, 2018</study_first_submitted>
  <study_first_submitted_qc>June 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2018</study_first_posted>
  <results_first_submitted>January 23, 2020</results_first_submitted>
  <results_first_submitted_qc>February 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 28, 2020</results_first_posted>
  <last_update_submitted>February 17, 2020</last_update_submitted>
  <last_update_submitted_qc>February 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT03570658/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy male Chinese subjects aged 18-60 years.</recruitment_details>
      <pre_assignment_details>Total n=31.
SAD n=28 (Active treatment n=22 and placebo n=6). 21 participants continued on to the MAD phase of the study. 3 participants chose not to continue.
MAD n=24. 3 participants were directly enrolled into the MAD phase of the study in addition to the 21 participants from the SAD phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants in both the MAD and SAD cohorts received placebo matched to RO7049389.</description>
        </group>
        <group group_id="P2">
          <title>RO7049389 - 200 mg</title>
          <description>Participants in the SAD cohort received a single 200 mg dose of RO7049389.</description>
        </group>
        <group group_id="P3">
          <title>RO7049389 - 400 mg/200 mg q12h</title>
          <description>Participants in the SAD cohort received a single 400 mg dose of RO7049389. Participants in the MAD cohort that formerly received the 400 mg single dose received 200 mg of RO7049389 every 12 hours (q12h) for 14 days.</description>
        </group>
        <group group_id="P4">
          <title>RO7049389 - 600 mg/400 mg q12h</title>
          <description>Participants in the SAD cohort only received a single 600 mg dose of RO7049389. Participants in the MAD cohort that formerly received the 600 mg single dose received 400 mg of RO7049389 q12h for 14 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Single Ascending Dose (SAD)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Multiple Ascending Dose (MAD)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Total n=31. SAD n=28. 21 participants continued and 3 new participants were directly enrolled in MAD (n=24). The 400/200 arm enrolled 2 new participants and the 600/400 arm enrolled 1. Baseline characteristics are split in to SAD and MAD to account for the 3 additional participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants in both the MAD and SAD cohorts received placebo matched to RO7049389.</description>
        </group>
        <group group_id="B2">
          <title>RO7049389 - 200 mg</title>
          <description>Participants in the SAD cohort received a single 200 mg dose of RO7049389.</description>
        </group>
        <group group_id="B3">
          <title>RO7049389 - 400 mg/200 mg q12h</title>
          <description>Participants in the SAD cohort received a single 400 mg dose of RO7049389. Participants in the MAD cohort that formerly received the 400 mg single dose received 200 mg of RO7049389 every 12 hours (q12h) for 14 days.</description>
        </group>
        <group group_id="B4">
          <title>RO7049389 - 600 mg/400 mg q12h</title>
          <description>Participants in the SAD cohort only received a single 600 mg dose of RO7049389. Participants in the MAD cohort that formerly received the 600 mg single dose received 400 mg of RO7049389 q12h for 14 days.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="11"/>
            <count group_id="B5" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>SAD participants</description>
          <population>The SAD population included 28 participants assigned to either placebo or active treatment.</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="10"/>
                    <count group_id="B5" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.2" spread="5.7"/>
                    <measurement group_id="B2" value="33.5" spread="6.4"/>
                    <measurement group_id="B3" value="30.2" spread="3.2"/>
                    <measurement group_id="B4" value="28.2" spread="6.0"/>
                    <measurement group_id="B5" value="29.5" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>MAD participants</description>
          <population>The MAD population included 24 participants assigned to either placebo or active treatment.</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="10"/>
                    <count group_id="B5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.8" spread="6.1"/>
                    <measurement group_id="B3" value="31.1" spread="3.3"/>
                    <measurement group_id="B4" value="29.0" spread="6.5"/>
                    <measurement group_id="B5" value="29.8" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>SAD participants</description>
          <population>The SAD population included 28 participants assigned to either placebo or active treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="10"/>
                    <count group_id="B5" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>MAD participants</description>
          <population>The MAD population included 24 participants assigned to either placebo or active treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="10"/>
                    <count group_id="B5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <description>SAD participants</description>
          <population>The SAD population included 28 participants assigned to either placebo or active treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="10"/>
                    <count group_id="B5" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <description>MAD participants</description>
          <population>The MAD population included 24 participants assigned to either placebo or active treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="10"/>
                    <count group_id="B5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>SAD participants</description>
          <population>The SAD population included 28 participants assigned to either placebo or active treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="10"/>
                    <count group_id="B5" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>MAD participants</description>
          <population>The MAD population included 24 participants assigned to either placebo or active treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="10"/>
                    <count group_id="B5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Adverse Events</title>
        <description>An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
        <time_frame>From the date of first administered dose through 28 days after the last administered dose.</time_frame>
        <population>All safety analyses were based on the safety analysis population, which included all subjects that received at least one dose of study medication (RO7049389 or placebo), with at least one safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>SAD - Placebo</title>
            <description>Participants received placebo matched to RO7049389.</description>
          </group>
          <group group_id="O2">
            <title>SAD RO7049389 - 200 mg</title>
            <description>Participants received a single 200 mg dose of RO7049389.</description>
          </group>
          <group group_id="O3">
            <title>SAD RO7049389 - 400 mg</title>
            <description>Participants received a single 400 mg dose of RO7049389.</description>
          </group>
          <group group_id="O4">
            <title>SAD RO7049389 - 600 mg</title>
            <description>Participants received a single 600 mg dose of RO7049389.</description>
          </group>
          <group group_id="O5">
            <title>MAD - Placebo</title>
            <description>Participants received placebo matched to RO7049389.</description>
          </group>
          <group group_id="O6">
            <title>MAD RO7049389 - 200 mg</title>
            <description>Participants received 200 mg of RO7049389 every 12 hours for 14 days.</description>
          </group>
          <group group_id="O7">
            <title>MAD RO7049389 - 400 mg</title>
            <description>Participants received 400 mg of RO7049389 every 12 hours for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events</title>
          <description>An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
          <population>All safety analyses were based on the safety analysis population, which included all subjects that received at least one dose of study medication (RO7049389 or placebo), with at least one safety assessment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="30.0"/>
                    <measurement group_id="O4" value="10.0"/>
                    <measurement group_id="O5" value="50.0"/>
                    <measurement group_id="O6" value="90.0"/>
                    <measurement group_id="O7" value="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of RO7049389</title>
        <time_frame>At pre-defined intervals on Day 1 (SAD) and Day 14 (MAD)</time_frame>
        <population>PK sampling was performed only once for single-dose (SAD) cohorts and did not include the placebo arms.</population>
        <group_list>
          <group group_id="O1">
            <title>SAD RO7049389 - 200 mg</title>
            <description>Participants received a single 200 mg dose of RO7049389.</description>
          </group>
          <group group_id="O2">
            <title>SAD RO7049389 - 400 mg</title>
            <description>Participants received a single 400 mg dose of RO7049389.</description>
          </group>
          <group group_id="O3">
            <title>SAD RO7049389 - 600 mg</title>
            <description>Participants received a single 600 mg dose of RO7049389.</description>
          </group>
          <group group_id="O4">
            <title>MAD RO7049389 - 200 mg</title>
            <description>Participants received 200 mg of RO7049389 every 12 hours for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>MAD RO7049389 - 400 mg</title>
            <description>Participants received 400 mg of RO7049389 every 12 hours for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of RO7049389</title>
          <population>PK sampling was performed only once for single-dose (SAD) cohorts and did not include the placebo arms.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3840" spread="41.3"/>
                    <measurement group_id="O2" value="5220" spread="84.8"/>
                    <measurement group_id="O3" value="4020" spread="116"/>
                    <measurement group_id="O4" value="3230" spread="40.6"/>
                    <measurement group_id="O5" value="9210" spread="51.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="2730" spread="35.4"/>
                    <measurement group_id="O5" value="8030" spread="60.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Observed Plasma Concentration (Tmax) of RO7049389</title>
        <time_frame>At pre-defined intervals on Day 1 (SAD) and Day 14 (MAD)</time_frame>
        <population>PK sampling was performed only once for single-dose (SAD) cohorts and did not include the placebo arms.</population>
        <group_list>
          <group group_id="O1">
            <title>SAD RO7049389 - 200 mg</title>
            <description>Participants received a single 200 mg dose of RO7049389.</description>
          </group>
          <group group_id="O2">
            <title>SAD RO7049389 - 400 mg</title>
            <description>Participants received a single 400 mg dose of RO7049389.</description>
          </group>
          <group group_id="O3">
            <title>SAD RO7049389 - 600 mg</title>
            <description>Participants received a single 600 mg dose of RO7049389.</description>
          </group>
          <group group_id="O4">
            <title>MAD RO7049389 - 200 mg</title>
            <description>Participants received 200 mg of RO7049389 every 12 hours for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>MAD RO7049389 - 400 mg</title>
            <description>Participants received 400 mg of RO7049389 every 12 hours for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Observed Plasma Concentration (Tmax) of RO7049389</title>
          <population>PK sampling was performed only once for single-dose (SAD) cohorts and did not include the placebo arms.</population>
          <units>Hours (h)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.5" upper_limit="1.5"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O3" value="2" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O4" value="1.5" lower_limit="1.5" upper_limit="2"/>
                    <measurement group_id="O5" value="2" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="2" lower_limit="1.5" upper_limit="2.02"/>
                    <measurement group_id="O5" value="2" lower_limit="1.5" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration vs Time Curve to Last Measurable Concentration (AUClast) of RO7049389</title>
        <time_frame>At pre-defined intervals on Day 1 (SAD) and Day 14 (MAD)</time_frame>
        <population>PK sampling was performed only once for single-dose (SAD) cohorts and did not include the placebo arms.</population>
        <group_list>
          <group group_id="O1">
            <title>SAD RO7049389 - 200 mg</title>
            <description>Participants received a single 200 mg dose of RO7049389.</description>
          </group>
          <group group_id="O2">
            <title>SAD RO7049389 - 400 mg</title>
            <description>Participants received a single 400 mg dose of RO7049389.</description>
          </group>
          <group group_id="O3">
            <title>SAD RO7049389 - 600 mg</title>
            <description>Participants received a single 600 mg dose of RO7049389.</description>
          </group>
          <group group_id="O4">
            <title>MAD RO7049389 - 200 mg</title>
            <description>Participants received 200 mg of RO7049389 every 12 hours for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>MAD RO7049389 - 400 mg</title>
            <description>Participants received 400 mg of RO7049389 every 12 hours for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration vs Time Curve to Last Measurable Concentration (AUClast) of RO7049389</title>
          <population>PK sampling was performed only once for single-dose (SAD) cohorts and did not include the placebo arms.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5960" spread="60.9"/>
                    <measurement group_id="O2" value="12200" spread="85.1"/>
                    <measurement group_id="O3" value="10800" spread="121"/>
                    <measurement group_id="O4" value="5090" spread="38"/>
                    <measurement group_id="O5" value="19400" spread="72.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="5460" spread="29.2"/>
                    <measurement group_id="O5" value="20900" spread="90.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration vs Time Curve Extrapolated to Infinity (AUC0-inf)</title>
        <time_frame>At pre-defined intervals on Day 1 (SAD) and Day 14 (MAD)</time_frame>
        <population>PK sampling was performed only once for single-dose (SAD) cohorts and did not include the placebo arms.</population>
        <group_list>
          <group group_id="O1">
            <title>SAD RO7049389 - 200 mg</title>
            <description>Participants received a single 200 mg dose of RO7049389.</description>
          </group>
          <group group_id="O2">
            <title>SAD RO7049389 - 400 mg</title>
            <description>Participants received a single 400 mg dose of RO7049389.</description>
          </group>
          <group group_id="O3">
            <title>SAD RO7049389 - 600 mg</title>
            <description>Participants received a single 600 mg dose of RO7049389.</description>
          </group>
          <group group_id="O4">
            <title>MAD RO7049389 - 200 mg</title>
            <description>Participants received 200 mg of RO7049389 every 12 hours for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>MAD RO7049389 - 400 mg</title>
            <description>Participants received 400 mg of RO7049389 every 12 hours for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration vs Time Curve Extrapolated to Infinity (AUC0-inf)</title>
          <population>PK sampling was performed only once for single-dose (SAD) cohorts and did not include the placebo arms.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9460" spread="NA">NA = there was only one participant sample.</measurement>
                    <measurement group_id="O2" value="12300" spread="84.6"/>
                    <measurement group_id="O3" value="11100" spread="120"/>
                    <measurement group_id="O4" value="5180" spread="37.7"/>
                    <measurement group_id="O5" value="19500" spread="72.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="5470" spread="29.1"/>
                    <measurement group_id="O5" value="20900" spread="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Half-Life (T1/2) of RO7049389</title>
        <time_frame>At pre-defined intervals on Day 1 (SAD) and Day 14 (MAD)</time_frame>
        <population>PK sampling was performed only once for single-dose (SAD) cohorts and did not include the placebo arms.</population>
        <group_list>
          <group group_id="O1">
            <title>SAD RO7049389 - 200 mg</title>
            <description>Participants received a single 200 mg dose of RO7049389.</description>
          </group>
          <group group_id="O2">
            <title>SAD RO7049389 - 400 mg</title>
            <description>Participants received a single 400 mg dose of RO7049389.</description>
          </group>
          <group group_id="O3">
            <title>SAD RO7049389 - 600 mg</title>
            <description>Participants received a single 600 mg dose of RO7049389.</description>
          </group>
          <group group_id="O4">
            <title>MAD RO7049389 - 200 mg</title>
            <description>Participants received 200 mg of RO7049389 every 12 hours for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>MAD RO7049389 - 400 mg</title>
            <description>Participants received 400 mg of RO7049389 every 12 hours for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Half-Life (T1/2) of RO7049389</title>
          <population>PK sampling was performed only once for single-dose (SAD) cohorts and did not include the placebo arms.</population>
          <units>Hours (h)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.66" spread="0"/>
                    <measurement group_id="O2" value="7.98" spread="97.8"/>
                    <measurement group_id="O3" value="10.4" spread="108"/>
                    <measurement group_id="O4" value="2.29" spread="39.4"/>
                    <measurement group_id="O5" value="1.62" spread="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="5.06" spread="31.6"/>
                    <measurement group_id="O5" value="6.74" spread="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance (CL/F) of RO7049389</title>
        <time_frame>At pre-defined intervals on Day 1 (SAD)</time_frame>
        <population>This parameter was not collected for the MAD cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>SAD RO7049389 - 200 mg</title>
            <description>Participants received a single 200 mg dose of RO7049389.</description>
          </group>
          <group group_id="O2">
            <title>SAD RO7049389 - 400 mg</title>
            <description>Participants received a single 400 mg dose of RO7049389.</description>
          </group>
          <group group_id="O3">
            <title>SAD RO7049389 - 600 mg</title>
            <description>Participants received a single 600 mg dose of RO7049389.</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance (CL/F) of RO7049389</title>
          <population>This parameter was not collected for the MAD cohort.</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1" spread="0"/>
                    <measurement group_id="O2" value="32.6" spread="58.2"/>
                    <measurement group_id="O3" value="53.9" spread="61.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Plasma Concentration (Ctrough) of RO7049389</title>
        <time_frame>At pre-defined intervals on Day 14 (MAD)</time_frame>
        <population>This outcome measure applied to arms receiving RO7049389 during the MAD phase.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD RO7049389 - 200 mg</title>
            <description>Participants received 200 mg of RO7049389 every 12 hours for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>MAD RO7049389 - 400 mg</title>
            <description>Participants received 400 mg of RO7049389 every 12 hours for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Plasma Concentration (Ctrough) of RO7049389</title>
          <population>This outcome measure applied to arms receiving RO7049389 during the MAD phase.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1" spread="29.8"/>
                    <measurement group_id="O2" value="66.1" spread="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accumulation Index of RO7049389</title>
        <time_frame>At pre-defined intervals on Day 14 (MAD)</time_frame>
        <population>This parameter was not collected for SAD cohorts.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD RO7049389 - 200 mg</title>
            <description>Participants received 200 mg of RO7049389 every 12 hours for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>MAD RO7049389 - 400 mg</title>
            <description>Participants received 400 mg of RO7049389 every 12 hours for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Index of RO7049389</title>
          <population>This parameter was not collected for SAD cohorts.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MAD Cohorts - Day 14 Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.846" spread="76.9"/>
                    <measurement group_id="O2" value="0.872" spread="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAD Cohorts - Day 14 AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="47"/>
                    <measurement group_id="O2" value="1.05" spread="37.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration vs Time Curve for a Dosing Interval (AUCtau)</title>
        <time_frame>At pre-defined intervals on Day 14 (MAD)</time_frame>
        <population>This parameter was not collected for SAD cohorts.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD RO7049389 - 200 mg</title>
            <description>Participants received 200 mg of RO7049389 every 12 hours for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>RO7049389 - 400 mg</title>
            <description>Participants in the SAD cohort received a single 400 mg dose of RO7049389, followed by a 1-week washout period. Participants in the MAD cohort that formerly received the 600 mg single dose received 400 mg of RO7049389 every 12 hours for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration vs Time Curve for a Dosing Interval (AUCtau)</title>
          <population>This parameter was not collected for SAD cohorts.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MAD Cohorts - Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5090" spread="38"/>
                    <measurement group_id="O2" value="19400" spread="72.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAD Cohorts - Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5230" spread="29.7"/>
                    <measurement group_id="O2" value="20400" spread="90.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the date of first administered dose through 28 days after the last administered dose.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SAD - Placebo</title>
          <description>Participants received placebo matched to RO7049389.</description>
        </group>
        <group group_id="E2">
          <title>SAD RO7049389 - 200 mg</title>
          <description>Participants received a single 200 mg dose of RO7049389.</description>
        </group>
        <group group_id="E3">
          <title>SAD RO7049389 - 400 mg</title>
          <description>Participants received a single 400 mg dose of RO7049389.</description>
        </group>
        <group group_id="E4">
          <title>SAD RO7049389 - 600 mg</title>
          <description>Participants received a single 600 mg dose of RO7049389.</description>
        </group>
        <group group_id="E5">
          <title>MAD - Placebo</title>
          <description>Participants received placebo matched to RO7049389</description>
        </group>
        <group group_id="E6">
          <title>MAD RO7049389 - 200 mg</title>
          <description>Participants received 200 mg of RO7049389 every 12 hours for 14 days.</description>
        </group>
        <group group_id="E7">
          <title>MAD RO7049389 - 400 mg</title>
          <description>Participants received 400 mg of RO7049389 every 12 hours for 14 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lip dry</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Eosinophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Eosinophil percentage increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urinary casts present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Bilirubin conjugated increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800-821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

